Luminal and Mucosal-Associated Intestinal Microbiota in Patients With Diarrhea-Predominant Irritable Bowel Syndrome

Gut Pathogens - United Kingdom
doi 10.1186/1757-4749-2-19
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Eluxadoline in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2017English

The Intestinal Microbiota and Probiotics in Irritable Bowel Syndrome

Scandinavian Journal of Nutrition
2004English

Two Case Reports of Patients With Diarrhea-Predominant Irritable Bowel Syndrome Treated With Jeoreongchajeonja-Tang

The Journal of Internal Korean Medicine
2019English

Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome

Gastroenterology
HepatologyGastroenterology
2017English

Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease

Frontiers in Microbiology
Microbiology
2019English

Review: Optimizing Outcomes With Alosetron Hydrochloride in Severe Diarrhea-Predominant Irritable Bowel Syndrome

Therapeutic Advances in Gastroenterology
Gastroenterology
2010English

Correlation Between Anxiety-Depression Status and Cytokines in Diarrhea-Predominant Irritable Bowel Syndrome

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2013English

Fecal Microbiota of Diarrhea-Predominant Irritable Bowel Syndrome Patients Causes Hepatic Inflammation of Germ-Free Rats and Berberine Reverses It Partially

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2019English

Clinical Potential of Eluxadoline in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

Therapeutics and Clinical Risk Management
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy